« Back
Home /
Human tissue plasminogen activator

Human tissue plasminogen activator

Item no.	THP-0135
Manufacturer	Creative BioMart
Amount	1ea
Category	Peptides & Proteins Recombinant Proteins
Type	Proteins
Specific against	Hu
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	133652-38-7
Similar products	133652-38-7
Available
Description	Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. The product is genetically engineered to retain and delete certain portions of human tPA. The product is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. The product contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from the product - kringle-1, finger, and epidermal growth factor (EGF).
Formula	C1736H2671N499O522S22
Sequences	SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP
CAS No.	133652-38-7
Molecular Weight	39589.6 Da
Synonyms	Human t-PA (residues 1-3 and 176-527); Reteplase, recombinant; Reteplase, recombinant
Applications info	For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction.
Examples of Clinical Use	Acute pulmonary emboli, intracoronary emboli and myocardial infarction
Pharmacodynamics	The product cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Mechanism of action	Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
Affected organisms	Humans and other mammals
Targets	Target 1. Plasminogen; Target 2. Fibrinogen alpha chain; Target 3. Urokinase plasminogen activator surface receptor; Target 4. Plasminogen activator inhibitor 1
Source	CHO

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1ea

available

Delivery expected until 10/4/2024

Express Delivery: Save 17 days

Compare

Add to wishlist

Recommend by mail